The DOI matches its OpenAlex record; 89 of the 89 references it cites were found in a registry or an index.
Extraintestinal manifestations and complications in inflammatory bowel diseases
Open accessAbstract
Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) that often involve organs other than those of the gastrointestinal tract. These nonintestinal affections are termed extraintestinal symptoms. Differentiating the true extraintestinal manifestations of inflammatory bowel diseases from secondary extraintestinal complications, caused by malnutrition, chronic inflammation or side effects of therapy, may be difficult. This review concentrates on frequency, clinical presentation and therapeutic implications of extraintestinal symptoms in inflammatory bowel diseases. If possible, extraintestinal manifestations are differentiated from extraintestinal complications. Special attention is given to the more recently described sites of involvement; i.e. thromboembolic events, osteoporosis, pulmonary involvement and affection of the central nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
GREENSTEIN, A. J., JANOWITZ, H. D., & SACHAR, D. B. (1976) · Medicine · doi:10.1097/00005792-197609000-00004 · Cited by 1,130
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study
Bernstein, C. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02319-x · Cited by 815
Cohen, S., Levy, R. M., Keller, M., Boling, E., Emkey, R. D., Greenwald, M., Zizic, T. M., Wallach, S., Sewell, K. L., Lukert, B. P., et al. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199911)42:11<2309::aid-anr8>3.0.co;2-k · Cited by 613
Reid, D. M., Hughes, R. A., Laan, R. F. J. M., Sacco-Gibson, N. A., Wenderoth, D. H., Adami, S., Eusebio, R. A., & Devogelaer, J.-P. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1006 · Cited by 592
Bernstein, C. N., Wajda, A., & Blanchard, J. F. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.021 · Cited by 569
Pardi, D. S., Loftus, E. V., Kremers, W. K., Keach, J., & Lindor, K. D. (2003) · Gastroenterology · doi:10.1053/gast.2003.50156 · Cited by 562
Orchard, T. R., Wordsworth, B. P., & Jewell, D. P. (1998) · Gut · doi:10.1136/gut.42.3.387 · Cited by 549
Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential
Broomé, U., Löfberg, R., Veress, B., & Eriksson, L. S. (1995) · Hepatology · doi:10.1002/hep.1840220511 · Cited by 481
Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?
Miehsler, W., Reinisch, W., Valic, E., Osterode, W., Tillinger, W., Feichtenschlager, T., Grisar, J., Machold, K., Scholz, S., Vogelsang, H., et al. (2004) · Gut · doi:10.1136/gut.2003.025411 · Cited by 479
Bernstein, C. N., Blanchard, J. F., Leslie, W., Wajda, A., & Yu, B. N. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-10-200011210-00012 · Cited by 474
Tung, B. Y., Emond, M. J., Haggitt, R. C., Bronner, M. P., Kimmey, M. B., Kowdley, K. V., & Brentnall, T. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00008 · Cited by 469
Reduced bone density in patients with inflammatory bowel disease.
Bjarnason, I., Macpherson, A., Mackintosh, C., Buxton-Thomas, M., Forgacs, I., & Moniz, C. (1997) · Gut · doi:10.1136/gut.40.2.228 · Cited by 360
Duerr, R. H., Targan, S. R., Landers, C. J., Larusso, N. F., Lindsay, K. L., Wiesner, R. H., & Shanahan, F. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)70028-v · Cited by 357
Ransford, R., & Langman, M. J. S. (2002) · Gut · doi:10.1136/gut.51.4.536 · Cited by 355
Oral budesonide is as effective as oral prednisolone in active Crohn’s disease
Campieri, M., Ferguson, A., Doe, W., Persson, T., Nilsson, L.-G., & the Global Budesonide Study Group (1997) · Gut · doi:10.1136/gut.41.2.209 · Cited by 324
Venous Thromboembolism in Inflammatory Bowel Disease
Solem, C. A., Loftus, E. V., Tremaine, W. J., & Sandborn, W. J. (2004) · American Journal of Gastroenterology · doi:10.1046/j.1572-0241.2003.04026.x · Cited by 317
Suhler, E. B. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.7.903 · Cited by 306
Osteoporosis in patients with inflammatory bowel disease.
Compston, J. E., Judd, D., Crawley, E. O., Evans, W. D., Evans, C., Church, H. A., Reid, E. M., & Rhodes, J. (1987) · Gut · doi:10.1136/gut.28.4.410 · Cited by 305
Genetic markers may predict disease behavior in patients with ulcerative colitis
Roussomoustakaki, M., Satsangi, J., Welsh, K., Louis, E., Fanning, G., Targan, S., Landers, C., & Jewell, D. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9178675 · Cited by 275
Neurologic Aspects of Inflammatory Bowel Disease
Lossos, A., River, Y., Eliakim, A., & Steiner, I. (1995) · Neurology · doi:10.1212/wnl.45.3.416 · Cited by 273
Survival and causes of death in patients with inflammatory bowel disease: A population-based study
Ekbom, A., Helmick, C. G., Zack, M., Holmberg, L., & Adami, H.-O. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90029-x · Cited by 265
Increased Risk for Demyelinating Diseases in Patients With Inflammatory Bowel Disease
Gupta, G., Gelfand, J. M., & Lewis, J. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.022 · Cited by 265
Logan, R. F., & van Staa, T. P. (2003) · Gut · doi:10.1136/gut.52.10.1530 · Cited by 262
The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects.
Mielants, H., VEYS, E. M., De Vos, M., et al. (1995) · PubMed · Cited by 261
MAUGARS, Y., MATHIS, C., BERTHELOT, J.-M., CHARLIER, C., & PROST, A. (1996) · Rheumatology · doi:10.1093/rheumatology/35.8.767 · Cited by 261
Unexplained Bronchopulmonary Disease With Inflammatory Bowel Disease
Kraft, S. C. (1976) · Archives of Internal Medicine · doi:10.1001/archinte.136.4.454 · Cited by 255
Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.
K, D. V., Mielants, H., Cuvelier, C. A., De Keyser, F., Veys, E. M., & De Vos, M. (2000) · PubMed · Cited by 247
Inflammatory bowel disease and the risk of fracture
Van staa, T.-P., Cooper, C., Samuels Brusse, L., Leufkens, H., Javaid, M. K., & Arden, N. K. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.027 · Cited by 245
Clinical patterns of familial inflammatory bowel disease.
Satsangi, J., Grootscholten, C., Holt, H., & Jewell, D. P. (1996) · Gut · doi:10.1136/gut.38.5.738 · Cited by 238
Pulmonary Manifestations of Inflammatory Bowel Disease
Storch, I., Sachar, D., & Katz, S. (2003) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200303000-00004 · Cited by 237
Metabolic bone assessment in patients with inflammatory bowel disease
Abitbol, V., Roux, C., Chaussade, S., Guillemant, S., Kolta, S., Dougados, M., Couturier, D., & Amor, B. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90068-3 · Cited by 235
Clinical and radiological characteristics of lung disease in inflammatory bowel disease
Mahadeva, R., Walsh, G., Flower, C. D. R., & Shneerson, J. M. (2000) · European Respiratory Journal · doi:10.1034/j.1399-3003.2000.15a09.x · Cited by 222
Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease
Regueiro, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00430-1 · Cited by 221
Winther, K. V., Jess, T., Langholz, E., Munkholm, P., & Binder, V. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.036 · Cited by 209
Femoral neck osteopenia in patients with inflammatory bowel disease
Dresner Pollak, R. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00349-9 · Cited by 206
Survival and cause-specific mortality in inflammatory bowel disease: A population-based cohort study
Persson, P., Bernell, O., Leijonmarck, C., Farahmand, B., Hellers, G., & Ahlbom, A. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613037 · Cited by 174
5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study☆
Van Staa, T. P., Travis, S., Leufkens, H. G. M., & Logan, R. F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.016 · Cited by 168
Comparative Tolerability of Treatments for Inflammatory Bowel Disease
Stein, R. B., & Hanauer, S. B. (2000) · Drug Safety · doi:10.2165/00002018-200023050-00006 · Cited by 167
Hepatobiliary Dysfunction and Primary Sclerosing Cholangitis in Patients with Crohn's Disease
Rasmussen, H. H., Fallingborg, J. F., Mortensen, P. B., Vyberg, M., Tage-Jensen, U., & Rasmussen, S. N. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709025107 · Cited by 166
Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease
Haderslev, K. V., Tjellesen, L., Sørensen, H. A., & Staun, M. (2000) · Gastroenterology · doi:10.1053/gast.2000.16518 · Cited by 150
Low bone mineral density in patients with inflammatory bowel disease
Pigot, F., Roux, C., Chaussade, S., Hardelin, D., Pelleter, O., Montbrun, T. D. P., Listrat, V., Dougados, M., Couturier, D., & Amor, B. (1992) · Digestive Diseases and Sciences · doi:10.1007/bf01296010 · Cited by 148
Generini, S., Giacomelli, R., Fedi, R., Fulminis, A., Pignone, A. M., Frieri, G., Rosso, A. D., Viscido, A., Galletti, B., Fazzi, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.012450 · Cited by 142
Mendoza, J. L., Lana, R., Taxonera, C., Alba, C., Izquierdo, S., & Díaz‐Rubio, M. (2005) · Medicina Clínica · doi:10.1157/13078423 · Cited by 136
STÖCKER, W., Otte, M., Ulrich, S., Normann, D., Finkbeiner, H., Stöcker, K., Jantschek, G., & Scriba, P. C. (1987) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528709089774 · Cited by 135
BONE DISEASE AFTER JEJUNO-ILEAL BYPASS FOR OBESITY
Compston, J. E., Laker, M. F., Woodhead, J. S., Gazet, J. C., Horton, L. W. L., Ayers, A. B., Bull, H. J., & Pilkington, T. R. E. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91318-1 · Cited by 128
A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody
Bhagat, S., & Das, K. M. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90066-3 · Cited by 128
Vogelsang, H., Ferenci, P., Resch, H., Kiss, A., & Gangl, A. (1995) · PubMed · Cited by 126
Herrlinger, K. R., Noftz, M. K., Dalhoff, K., Ludwig, D., Stange, E. F., & Fellermann, K. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05473.x · Cited by 126
Self-citationFocal white-matter lesions in brain of patients with inflammatory bowel disease
Andus, T., Roth, M., Kullmann, F., Caesar, I., Gross, V., Feuerbach, S., Schölmerich, J., Geißler, A., & Held, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90013-6 · Cited by 126
Bone loss in patients with inflammatory bowel disease: A prospective study
Roux, C., Abitbol, V., Chaussade, S., Kolta, S., Guillemant, S., Dougados, M., Amor, B., & Couturier, D. (1995) · Osteoporosis International · doi:10.1007/bf02106094 · Cited by 125
Demyelination During Anti-Tumor Necrosis Factor α Therapy With Infliximab for Crohn's Disease
Thomas, C. W., Weinshenker, B. G., & Sandborn, W. J. (2003) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200401000-00004 · Cited by 118
r, N. S., r, Y. S., n, M. T. Z., Do??an, I., n, D. T. Z., Ensarı, A., & Hekįmoğlu, B. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200310000-00006 · Cited by 112
Concurrence of Inflammatory Bowel Disease and Multiple Sclerosis
Kimura, K. B., Hunter, S. F., Thollander, M. S., Loftus, E. V., Melton, L. J., O’Brien, P. C., Rodriguez, M., & Phillips, S. F. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.8.802 · Cited by 111
(2003) · Gastroenterology · doi:10.1053/gast.2003.50107 · Cited by 111
Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis
Marzo‐Ortega, H., McGonagle, D., O'Connor, P., & Emery, P. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.1.74 · Cited by 108
Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease.
Clements, D. S., Compston, J., Evans, W. D., & Rhodes, J. (1993) · Gut · doi:10.1136/gut.34.11.1543 · Cited by 107
ASSOCIATION OF ULCERATIVE COLITIS WITH MULTIPLE SCLEROSIS
Rang, E. H., Brooke, Β. N., & Hermon-Taylor, J. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90629-8 · Cited by 104
Concurrence of Multiple Sclerosis and Inflammatory Bowel Disease
Schiliro, G., Volti, S. L., Marino, S., Dibenedetto, S. P., Samperi, P., Testa, R., & Mollica, F. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909143211115 · Cited by 97
Jahnsen, J., Falch, J. A., Mowinckel, P., & Aadland, E. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520310007873 · Cited by 96
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies
Kruithof, E., Rycke, L. D., Roth, J., Mielants, H., den Bosch, F. E. V., Keyser, F. D., VEYS, E. M., & Baeten, D. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21426 · Cited by 90
Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
Adachi, J. D., Cranney, A., Ch, G., Wg, B., Bianchi, F. A., Cividino, A. A., Gl, C., Kamińska, E., Sebaldt, R. J., & Παπαϊωάννου, Α. (1994) · PubMed · Cited by 89
Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab
Fries, W., Giofré, M. R., Catanoso, M., & Gullo, R. L. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05514.x · Cited by 85
A four-year longitudinal study of bone loss in patients with inflammatory bowel disease
Motley, R., Clements, D. S., Evans, W. D., Crawley, E. O., Evans, C., Rhodes, J., & Compston, J. E. (1993) · Bone and Mineral · doi:10.1016/s0169-6009(08)80046-3 · Cited by 85
Peeters, H., Cruyssen, B. V., Laukens, D., Coucke, P. J., Marichal, D., Berghe, M. V. D., Cuvelier, C. A., Remaut, E., Mielants, H., Keyser, F. D., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.021774 · Cited by 83
Siffledeen, J. S., Fedorak, R. N., Siminoski, K. G., Jen, H., Vaudan, E., Abraham, N. S., Seinhart, H., & Greenberg, G. R. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200405000-00007 · Cited by 82
Marteau, P. R., Nelet, F., LU, M. L., & DEVAUX, C. (1996) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1996.92264000.x · Cited by 81
Increased bone resorption in patients with Crohn’s disease
Робинсон, Iqbal, Abrams, K. R., Al‐Azzawi, & Mayberry, J. F. (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00364.x · Cited by 79
Herrlinger, K. R., Noftz, M. K., Fellermann, K., Schmidt, K. J., Steinhoff, J., & Stange, E. F. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.00940.x · Cited by 77
Self-citationThe use of induced sputum in the assessment of pulmonary involvement in Crohn's disease
Fireman, Z., Osipov, A., Kivity, S., Kopelman, Y., Sternberg, A., Lazarov, E., & Fireman, E. M. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01843.x · Cited by 72
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND INFLAMMATORY BOWEL DISEASE: CURRENT PERSPECTIVES
Cipolla, G. (2002) · Pharmacological Research · doi:10.1016/s1043-6618(02)00033-6 · Cited by 72
Pancreatic Autoantibodies in Inflammatory Bowel Disease
Joossens, S. B. A., Vermeire, S. A. R. A., Steen, K. V., et al. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200411000-00012 · Cited by 72
Pancreatic function in chronic inflammatory bowel disease
Angelini, G., Cavallini, G., Bovo, P., et al. (1988) · International Journal of Pancreatology · doi:10.1007/bf02798930 · Cited by 67
Pancreatic function in Crohn's disease.
Hegnhøj, J., Hansen, C. P., Rannem, T., et al. (1990) · Gut · doi:10.1136/gut.31.9.1076 · Cited by 66
Akbayır, N., Çalış, A. B., Alkım, C., Sokmen, H. M., Erdem, L., Özbal, A. E., BÖLÜKbaŞ, F., & Akbayır, N. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2964-3 · Cited by 63
Increased degradation of type I collagen in patients with inflammatory bowel disease.
Silvennoinen, J. I. K., Risteli, L., Karttunen, T. J., et al. (1996) · Gut · doi:10.1136/gut.38.2.223 · Cited by 61
Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies.
de Wit, A. W. M. V. M., van Deventer, S. J. H., & Tytgat, G. N. J. (1995) · PubMed · Cited by 60
Infliximab-Associated Retrobulbar Optic Neuritis
Mejico, L. J. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.5.793 · Cited by 59
An update on the diagnosis of osteoporosis
Kanis, J. A. (2000) · Current Rheumatology Reports · doi:10.1007/s11926-996-0070-y · Cited by 57
Ursodeoxycholic Acid Therapy in Treatment of Primary Sclerosing Cholangitis
Stiehl, A. (1994) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529409103626 · Cited by 40
Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease.
Vestergaard, P. (2004) · PubMed · Cited by 39
[Pathological bone density in chronic inflammatory bowel diseases--prevalence and risk factors].
von Tirpitz, C., Pischulti, G., Klaus, J., Rieber, A., Brückel, J., Böhm, B. O., Adler, G., & Reinshagen, M. (1999) · PubMed · Cited by 35
Peripheral neuropathy associated with Crohn's disease
Nemni, R., Fazio, R., Corbo, M., et al. (1987) · Neurology · doi:10.1212/wnl.37.8.1414 · Cited by 35
Osteoporosis and Crohn’s disease
Sahli, H., Meddeb, N., Faten, L., et al. (2004) · Joint Bone Spine · doi:10.1016/j.jbspin.2004.09.006 · Cited by 32
Acute autoimmune sensorineural hearing loss associated with Crohn's disease
Bachmeyer, C., Leclerc-Landgraf, N., Laurette, F., Coutarel, P., Cadranel, J.-F., Médioni, J., Dhôte, R., & Mougeot-Martin, M. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00720.x · Cited by 30
Nephrotic Syndrome in Ulcerative Colitis
Stokke, K. T., Teisberg, P., Myhre, E. S. P., Hovig, T., Flatmark, A. L., & Gjone., E. (1976) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.1976.12097153 · Cited by 29
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Cited by
Extraintestinal Manifestations of Inflammatory Bowel Disease
Vavricka, S. R., Schoepfer, A., Scharl, M., Lakatos, P. L., Navarini, A., & Rogler, G. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000392 · Cited by 909
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Wang, Y., Parker, C. E., Bhanji, T., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000543.pub4 · Cited by 494
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Wang, Y., Parker, C. E., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000544.pub4 · Cited by 483
Pulmonary-intestinal cross-talk in mucosal inflammatory disease
Keely, S., Talley, N. J., & Hansbro, P. M. (2012) · Mucosal Immunology · doi:10.1038/mi.2011.55 · Cited by 386
Extraintestinal manifestations and complications in IBD
Ott, C., & Schölmerich, J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.117 · Cited by 351
Metadata
- Authors
- Rothfuss, K., Stange, E. F., & Herrlinger, K. R.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group
- Published
- 2006-01-01
- Volume
- 12
- Issue
- 30
- Pages
- 4819-4819
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W1571166414
- Cited by
- 359
- References
- 89
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.